Erythrocyte cAMP in Determining Frequency of Acute Pain Episodes in Sickle Cell Disease Patients from Odisha State, India

Abstract Vaso-occlusive crisis (VOC) occurs more frequently during stress in sickle cell disease patients. Epinephrine released during stress increases adhesion of sickled red blood cells (RBCs) to endothelium and to leukocytes, a process mediated through erythrocyte cyclic adenosine monophosphate (cAMP). Increased adhesion of sickled RBCs retards blood flow through the capillaries and promotes vaso-occlusion. Therefore, we examined the association of RBC-cAMP levels with frequency of acute pain episodes in sickle cell disease subjects. Using a case control study design, we measured RBC-cAMP levels, fetal hemoglobin (Hb F), α-thalassemia (α-thal) and other hematological parameters at baseline (sham treated) and after stimulation with epinephrine. The cases consisted of sickle cell disease subjects with three or more acute pain episodes in the last 12 months, and those without a single acute pain episode in the last 12 months were considered as controls. Significantly higher cAMP values were found in cases than the controls, in both sham treated (p < 0.001) and epinephrine treated RBCs (p < 0.001) by Wilcoxon Rank Sum test. However, significant association of cAMP values was observed both on univariate [odds ratio (OR): 4.8, 95% confidence interval (95% CI): 1.51-15.19, p < 0.008) and multivariate logistic regression analyses only in epinephrine treated (OR: 5.07, 95% CI: 1.53-16.82, p < 0.008) but not in sham-treated RBCs. In the covariates, Hb F consistently showed protective effects in univariate as well as in multivariate analyses. Frequent acute pain episodes are associated with higher cAMP levels than those with less frequent pain episodes, only after stimulation with epinephrine but not with baseline level.

[1]  P. Das,et al.  Association of fetal hemoglobin level with frequency of acute pain episodes in sickle cell disease (HbS-only phenotype) patients. , 2019, Blood cells, molecules & diseases.

[2]  M. Gladwin,et al.  Pathophysiology of Sickle Cell Disease. , 2019, Annual review of pathology.

[3]  M. Steinberg,et al.  Fetal hemoglobin in sickle cell anemia: The Arab‐Indian haplotype and new therapeutic agents , 2017, American journal of hematology.

[4]  Hillel W. Cohen,et al.  Elevated Steady State WBC and Platelet Counts Are Associated with Frequent Emergency Room Use in Adults with Sickle Cell Anemia , 2015, PloS one.

[5]  G. Lykotrafitis,et al.  AKAP-dependent modulation of BCAM/Lu adhesion on normal and sickle cell disease RBCs revealed by force nanoscopy. , 2014, Biophysical journal.

[6]  P. Purohit,et al.  Prevalence of Deletional Alpha Thalassemia and Sickle Gene in a Tribal Dominated Malaria Endemic Area of Eastern India , 2014, ISRN hematology.

[7]  J. Elion,et al.  Hydroxycarbamide Decreases Sickle Reticulocyte Adhesion to Resting Endothelium by Inhibiting Endothelial Lutheran/Basal Cell Adhesion Molecule (Lu/BCAM) through Phosphodiesterase 4A Activation* , 2014, The Journal of Biological Chemistry.

[8]  O. Oshinaike,et al.  Haematological values in homozygous sickle cell disease in steady state and haemoglobin phenotypes AA controls in Lagos, Nigeria , 2012, BMC Research Notes.

[9]  Mike A Laffan Dm Frcp FRCPath,et al.  Dacie and Lewis Practical Haematology , 2012 .

[10]  R. Lefkowitz,et al.  Therapeutic potential of β-arrestin- and G protein-biased agonists. , 2011, Trends in molecular medicine.

[11]  J. Elion,et al.  [Pathophysiology of sickle cell disease]. , 2010, Medecine tropicale : revue du Corps de sante colonial.

[12]  D. Bachir,et al.  Decreased sickle red blood cell adhesion to laminin by hydroxyurea is associated with inhibition of Lu/BCAM protein phosphorylation. , 2010, Blood.

[13]  Keshava Rajagopal,et al.  Teaching old receptors new tricks: biasing seven-transmembrane receptors , 2010, Nature Reviews Drug Discovery.

[14]  ��� S������i gene analysis. , 2010 .

[15]  D. Kaul,et al.  Sickle Red Cell–Endothelium Interactions , 2009, Microcirculation.

[16]  A. Ashley-Koch,et al.  β2‐Adrenergic receptor and adenylate cyclase gene polymorphisms affect sickle red cell adhesion , 2008, British journal of haematology.

[17]  J. Elion,et al.  Erythroid adhesion molecules in sickle cell disease: effect of hydroxyurea. , 2008, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[18]  M. Dewhirst,et al.  Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in vivo. , 2007, Blood.

[19]  M. Telen Role of adhesion molecules and vascular endothelium in the pathogenesis of sickle cell disease. , 2007, Hematology. American Society of Hematology. Education Program.

[20]  M. Steinberg Predicting clinical severity in sickle cell anaemia , 2005, British journal of haematology.

[21]  M. Telen,et al.  Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-αvβ3 interactions , 2004 .

[22]  K. Ataga,et al.  Mechanism of CD47-induced α4β1 Integrin Activation and Adhesion in Sickle Reticulocytes* , 2004, Journal of Biological Chemistry.

[23]  M. Telen,et al.  Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-alphavbeta3 interactions. , 2004, Blood.

[24]  M. Telen,et al.  Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion. , 2003, Blood.

[25]  J. Benovic Novel β2-adrenergic receptor signaling pathways , 2002 .

[26]  D. Mohanty,et al.  Sickle cell disease in India. , 1958, Blood.

[27]  L. Parise,et al.  Activation of sickle red blood cell adhesion via integrin-associated protein/CD47-induced signal transduction. , 2001, The Journal of clinical investigation.

[28]  D. Higgs,et al.  Single-tube multiplex-PCR screen for common deletional determinants of α-thalassemia , 2000 .

[29]  S Levin,et al.  β‐Adrenergic agonists regulate cell membrane fluctuations of human erythrocytes , 1999, The Journal of physiology.

[30]  M. Steinberg 6 Pathophysiology of sickle cell disease , 1998 .

[31]  O. Platt,et al.  Mortality in sickle cell disease. Life expectancy and risk factors for early death. , 1994, The New England journal of medicine.

[32]  E Vichinsky,et al.  Pain in sickle cell disease. Rates and risk factors. , 1991, The New England journal of medicine.

[33]  M. Caron,et al.  beta-Adrenergic receptor kinase. Activity of partial agonists for stimulation of adenylate cyclase correlates with ability to promote receptor phosphorylation. , 1988, The Journal of biological chemistry.

[34]  J. Hofrichter,et al.  Hemoglobin S gelation and sickle cell disease. , 1987, Blood.

[35]  S. Orkin,et al.  Molecular analysis of the high-hemoglobin-F phenotype in Saudi Arabian sickle cell anemia. , 1987, The New England journal of medicine.

[36]  A. Gilman,et al.  G proteins: transducers of receptor-generated signals. , 1987, Annual review of biochemistry.

[37]  H. Bunn,et al.  Hemoglobin: Molecular, Genetic and Clinical Aspects , 1984 .